Genetic testing for melanoma predisposition: Current challenges

Cancer Nursing

Volumn 30, Issue 6, 2007, Pages 454-461

  Gerstenblith, Meg R ^a   Goldstein, Alisa M ^a   Tucker, Margaret A ^a   Fraser, Mary C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDK4; CDKN2A; Familial melanoma; Genetic testing; Melanoma susceptibility genes; Multiple primary melanoma; Risk assessment counseling

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MELANOMA; ONCOLOGY NURSING; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; SUN EXPOSURE; UNITED STATES;

EID: 36348954974     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NCC.0000300165.98391.e7     Document Type: Article

References (54)

1. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene. 2003;22:3042-3052.
2. Surveillance Epidemiology and End Results, NCI. (1975-2001). SEER cancer statistics review, 1975-2001. http://seer.cancer.gov/csr/1975_2001. Accessed May 16, 2006.
3. Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2007. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007. http://www.cancer.org/downloads/STT/CAFF2007PWSecured. pdf. Accessed January 29, 2007.
4. Gruber SB, Armstrong BK. Cutaneous and ocular melanoma. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:1196-1229.
5. Fears TR, Bird CC, Guerry D, et al. Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res. 2002;62:3992-3996.
6. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999;17:3245-3251.
7. Goldstein AM, Tucker MA. Familial melanoma and its management. In: Eeles RA, Easton DF, Ponder BAJ, Eng C, eds. Genetic Predisposition to Cancer. London: Edward Arnold Publishers Ltd; 2004:352-359.
8. Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol. 2005;23:7168-7177.
9. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
10. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
11. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97-99.
12. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22:3053-3062.
13. Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet. 1998;7:209-216.
14. Molven A, Grimstvedt MB, Steine SJ, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer. 2005;44:10-18.
15. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000;92:1006-1010.
16. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003;73:301-313.
17. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. Adopted on February 20, 1996. J Clin Oncol. 1996;14:1730-1736.
18. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
19. Secretary's Advisory Committee on Genetic Testing. (1999-2000). A public consultation on oversight of genetic tests. http://www4.od.nih.gov/oba/sacgt/ reports/Public_Consultation_document.htm. Accessed May 16, 2006.
20. Kefford RF, Newton-Bishop JA, Tucker MA, et al. Genetic testing for melanoma (commentary). Lancet Oncol. 2002;3:653-654.
21. Riedijk SR, deSnoo FA, van Dijk S, et al. Hereditary melanoma and predictive genetic testing: why not? Psycho-Oncology. 2005;14:738-745.
22. de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer. 2003;2:109-116.
23. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol. 2003;15:157-161.
24. Hansen CB, Wadge LM, Lowstuter K, Boucher K, Leachman SA. Clinical germline genetic testing for melanoma. Lancet Oncol. 2004;5:314-319.
25. Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol. 2004;51:803-808.
26. Aitken J, Welch J, Duffy D, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst. 1999;91:446-452.
27. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst. 1997;89:1460.
28. Youl P, Aitken J, Hayward N, et al. Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer. 2002;98:92-98.
29. Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol. 2000;136:1118-1122.
30. Nagore E, Montoro A, Oltra S, et al. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Res. 2005;15:555-558.
31. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507-1515.
32. Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer. 1999;25:339-348.
33. Niendorf K, Goggins W, Yang G, et al. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet. 2006;43:501-506.
34. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents [epub ahead of print]. J Med Genet. 2006.
35. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
36. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765-773.
37. Chaudru V, Laud K, Avril MF, et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev. 2005;14:2384-2390.
38. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanomaprone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005;14:2208-2212.
39. Goldstein AM, Martinez M, Tucker MA, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev. 2000;9:889-894.
40. van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001;69:774-779.
41. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818-9828.
42. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260-1266.
43. Vasen HF, Gruis NA, Frants RR, Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.
44. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: improvements in our understanding of genetics and screening. Int J Biochem Cell Biol. 2004;36:1386-1392.
45. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247-255.
46. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-621.
47. Hruban RH, Canto MI, Griffin C, et al. Treatment of familial pancreatic cancer and its precursors. Curr Treat Options Gastroenterol. 2005;8:365-375.
48. Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol. 2003;139:1019-1025.
49. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/Familial high-risk assessment: breast and ovarian. Version 1. 2006. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening. pdf. Accessed May 16, 2006.
50. Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol. 2006;57:1-23.
51. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
52. Tucker MA, Fraser MC, Goldstein AM, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer. 2002;94:3192-3209.
53. Loud JT, Peters JA, Fraser M, Jenkins J. Applications of advances in molecular biology and genomics to clinical cancer care. Cancer Nurs. 2002;25:110-122.
54. Freedman DM, Miller BA, Tucker MA. New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. In: Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006:339-362. NIH Publ. No. 05-5302.